KOPRANKopran Limited
Pharma · Drug Manufacturers - General · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, penicillin, quinolone, anti-protozoal, sulphonamides, respiratory, tetracycline, cardiovascular, anti-diabetic, urology, pain management and anti-inflammatory, gastrointestinal, erectile dysfunction, anthemintic, anti-allergic, central nervous system, anti-malarial, anti-thyroid, and carbapenems. In addition, the company offers drugs for anti-hypertensive, neuromodulator, anti-acne, anti-infective, antibiotic, anti-thrombotic, anti-diabetic, anti-asthamatic, antihyperlipidemic, anti-convulsants, anti-anxiety, pulmonary arterial hypertension, chronic heart failure, neuropathic pain, and erosive esophagitis. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on KOPRAN — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Debt/Equity: 0.29
- • Price vs SMA50: above
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • 3-month return: +27.2%
- • 3-month vs NIFTY: +31.4% relative
Bull case
- • Debt/Equity: 0.29
- • Price vs SMA50: above
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
Bear case
- • Profit growth: -9.7% YoY
- • ROE: 4.9%
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Profit growth: -9.7% YoY
- • ROE: 4.9%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹16.62). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.